GL Pharm Tech Valuation

Is A204840 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A204840 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A204840's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A204840's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A204840?

Key metric: As A204840 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A204840. This is calculated by dividing A204840's market cap by their current revenue.
What is A204840's PS Ratio?
PS Ratio	2.8x
Sales	₩27.91b
Market Cap	₩78.02b

A204840 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3x
Enterprise Value/EBITDA	-52x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A204840's PS Ratio compare to its peers?

The above table shows the PS ratio for A204840 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.6x
A001540 Ahn-Gook Pharmaceutical	0.3x	n/a	₩78.8b
A330350 WITHUS PHARMACEUTICALLTD	0.8x	n/a	₩89.0b
A007370 Jin Yang Pharmaceutical	0.6x	n/a	₩67.2b
A012790 Sinil Pharmaceutical	0.8x	n/a	₩75.4b
A204840 GL Pharm Tech	2.8x	n/a	₩78.0b

Price-To-Sales vs Peers: A204840 is expensive based on its Price-To-Sales Ratio (2.8x) compared to the peer average (0.6x).

Price to Sales Ratio vs Industry

How does A204840's PS Ratio compare vs other companies in the KR Pharmaceuticals Industry?

3 Companies	Price / Sales	Estimated Growth	Market Cap
A009290 Kwang Dong Pharmaceutical	0.1x	n/a	US$163.00m
A002620 Jeil Pharma Holdings	0.2x	n/a	US$95.63m
A000230 Ildong Holdings	0.1x	n/a	US$56.11m

No more companies available in this PS range

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A204840 is expensive based on its Price-To-Sales Ratio (2.8x) compared to the KR Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is A204840's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A204840 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A204840's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

J2KBIO

₩56.2b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,830.00

6.0%

n/a

Hugel

₩2.9t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩268,000.00

-3.4%

75.9%

Dong-A ST

₩560.3b

Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.

A170900

₩62,400.00

-1.9%

8.8%